COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line (1L) treatment for lower-risk myelodysplastic syndromes (LR-MDS).

EP: 1.Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

Now Viewing

EP: 2.COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

Video content above is prompted by the following:

Please discuss the updated data from the COMMANDS study presented at ASCO 2024.

• What is the importance of the outcome data for luspatercept vs epoetin alfa in 1L treatment? (Zeidan et al,
  J Clin Oncol. 2024; 42(suppl 16): 6565); (Della Porta et al, Lancet Haematol. 2024; 11:e646-658.)

Recent Videos